Delgocitinib Cream Becomes First, Only Approved Treatment for Moderate-to-Severe Chronic Hand Eczema
July 24th 2025The approval represents a major advancement for patients with moderate-to-severe chronic hand eczema, as delgocitinib becomes the first treatment available for this population in the US.
Expert Discussion: Role of Pharmacists in Expanding Access to CAR T Therapies Without REMS
July 22nd 2025Debra Patt, MD, PhD, MBA, and Houston Holmes, MD, explore how the removal of risk evaluation and management strategies (REMS) for chimeric antigen receptor (CAR) T-cell (CAR T) therapies can improve health equity, expand access in community settings, and elevate the pharmacist’s role in care coordination.
FDA Panel Rejects Belantamab Mafodotin Combinations for Multiple Myeloma, Citing Safety Concerns
July 18th 2025The advisory committee cited concerns around ocular toxicity and overall tolerability, raising serious questions about the drug's benefit-risk profile ahead of its scheduled Prescription Drug User Fee Act action date on July 23, 2025.
Finerenone Approved by FDA for Treatment of Adults With Heart Failure
July 14th 2025Previously indicated to reduce the risk of end-stage kidney disease, cardiovascular death, and hospitalization for heart failure (HF) in chronic kidney disease, finerenone is now approved for patients with HF directly, offering a new treatment option.
Sunvozertinib Approved by FDA as Oral Treatment of NSCLC With EGFR Exon 20 Insertion Mutations
July 7th 2025Sunvozertinib becomes the first and only targeted approval treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations.